1. Home
  2. TBPH vs CYD Comparison

TBPH vs CYD Comparison

Compare TBPH & CYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • CYD
  • Stock Information
  • Founded
  • TBPH 2013
  • CYD 1951
  • Country
  • TBPH United States
  • CYD Singapore
  • Employees
  • TBPH N/A
  • CYD N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • CYD Industrial Machinery/Components
  • Sector
  • TBPH Health Care
  • CYD Industrials
  • Exchange
  • TBPH Nasdaq
  • CYD Nasdaq
  • Market Cap
  • TBPH 452.3M
  • CYD 401.8M
  • IPO Year
  • TBPH N/A
  • CYD 1994
  • Fundamental
  • Price
  • TBPH $9.32
  • CYD $20.00
  • Analyst Decision
  • TBPH Buy
  • CYD
  • Analyst Count
  • TBPH 4
  • CYD 0
  • Target Price
  • TBPH $13.75
  • CYD N/A
  • AVG Volume (30 Days)
  • TBPH 202.5K
  • CYD 231.0K
  • Earning Date
  • TBPH 02-26-2025
  • CYD 02-25-2025
  • Dividend Yield
  • TBPH N/A
  • CYD 1.90%
  • EPS Growth
  • TBPH N/A
  • CYD 14.53
  • EPS
  • TBPH N/A
  • CYD 1.17
  • Revenue
  • TBPH $63,192,000.00
  • CYD $2,639,608,357.00
  • Revenue This Year
  • TBPH $11.41
  • CYD $11.68
  • Revenue Next Year
  • TBPH $37.36
  • CYD $4.06
  • P/E Ratio
  • TBPH N/A
  • CYD $17.10
  • Revenue Growth
  • TBPH 15.93
  • CYD 15.32
  • 52 Week Low
  • TBPH $7.44
  • CYD $7.95
  • 52 Week High
  • TBPH $10.90
  • CYD $23.22
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 47.75
  • CYD 88.37
  • Support Level
  • TBPH $8.85
  • CYD $11.16
  • Resistance Level
  • TBPH $10.05
  • CYD $23.22
  • Average True Range (ATR)
  • TBPH 0.38
  • CYD 1.31
  • MACD
  • TBPH 0.01
  • CYD 0.89
  • Stochastic Oscillator
  • TBPH 38.75
  • CYD 75.08

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About CYD China Yuchai International Limited

China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International primarily operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.

Share on Social Networks: